Literature DB >> 22592533

Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Weiwei Shan1, Imelda Mercado-Uribe, Jing Zhang, Daniel Rosen, Shiwu Zhang, Jianjun Wei, Jinsong Liu.   

Abstract

Recent studies have suggested that some ovarian and pelvic serous carcinomas could originate from the fimbriated end of the distal fallopian tube. To test this hypothesis, we immortalized a normal human fallopian tube epithelial (FTE) cell line by using retrovirus-mediated overexpression of the early region of the SV40 T/t antigens and the human telomerase reverse transcriptase subunit (hTERT). These immortalized FTEs were then transformed by ectopic expression of oncogenic human HRAS (V12) . Tumorigenicity of the immortalized and/or transformed cells was subsequently tested by anchorage-independence growth assay and inoculation into nude mice via subcutaneous and intraperitoneal injection. As expected, the HRAS (V12) -transformed FTEs produced tumors through both subcutaneous and intraperitoneal injections, whereas no tumor growth was observed in immortalized FTEs. Unexpectedly, histopathological examination of tumors resulting from subcutaneous as well as intraperitoneal injections revealed largely poorly differentiated mucinous adenocarcinoma mixed with undifferentiated carcinoma. The tumor implants invaded extensively to the liver, colon, spleen, omentum, adrenal gland and renal capsule. Immunohistochemical staining of tumor cells showed positive staining for the epithelial cell markers cytokeratin AE1/AE3 and Müllerian lineage marker PAX8. Our study demonstrates that FTEs can generate poorly differentiated mucinous adenocarcinoma mixed with undifferentiated carcinoma through genetic modifications. Thus, we provide the first experimental evidence that fimbrial epithelial cells of the fallopian tube could be a potential source of ovarian mucinous adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592533      PMCID: PMC3368862          DOI: 10.4161/cc.20544

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

Review 3.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

4.  Mucosubstances in classification of serous and mucinous ovarian tumors: a morphometrical study.

Authors:  M L Aalto
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1986-07       Impact factor: 2.435

5.  Mucin histochemistry of ovarian mucinous cystadenomas expressing gastrointestinal characteristics.

Authors:  K Nomura
Journal:  Pathol Int       Date:  1995-06       Impact factor: 2.534

6.  Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors.

Authors:  Jeffrey D Seidman; Fatemeh Khedmati
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

7.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Authors:  Tan A Ince; Andrea L Richardson; George W Bell; Maki Saitoh; Samuel Godar; Antoine E Karnoub; James D Iglehart; Robert A Weinberg
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 8.  The ovarian surface epithelium: simple source of a complex disease.

Authors:  K C Choi; N Auersperg
Journal:  Minerva Ginecol       Date:  2003-08

9.  PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Authors:  Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842

Review 10.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  28 in total

Review 1.  Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.

Authors:  Helen H W Chen; Wen-Chung Chen; Zhang-Dong Liang; Wen-Bin Tsai; Yan Long; Isamu Aiba; Siqing Fu; Russell Broaddus; Jinsong Liu; Lynn G Feun; Niramol Savaraj; Macus Tien Kuo
Journal:  Expert Opin Ther Targets       Date:  2015-05-25       Impact factor: 6.902

2.  Three-dimensional modeling of the human fallopian tube fimbriae.

Authors:  Sharon L Eddie; Suzanne M Quartuccio; Jie Zhu; Jessica A Shepherd; Rajul Kothari; J Julie Kim; Teresa K Woodruff; Joanna E Burdette
Journal:  Gynecol Oncol       Date:  2014-12-16       Impact factor: 5.482

3.  Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.

Authors:  Yi A Ren; Lisa K Mullany; Zhilin Liu; Alan J Herron; Kwong-Kwok Wong; JoAnne S Richards
Journal:  Cancer Res       Date:  2016-03-10       Impact factor: 12.701

4.  In vivo tumor growth of high-grade serous ovarian cancer cell lines.

Authors:  Anirban K Mitra; David A Davis; Sunil Tomar; Lynn Roy; Hilal Gurler; Jia Xie; Daniel D Lantvit; Horacio Cardenas; Fang Fang; Yueying Liu; Elizabeth Loughran; Jing Yang; M Sharon Stack; Robert E Emerson; Karen D Cowden Dahl; Maria V Barbolina; Kenneth P Nephew; Daniela Matei; Joanna E Burdette
Journal:  Gynecol Oncol       Date:  2015-06-05       Impact factor: 5.482

5.  miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Authors:  Zhaojian Liu; Elizabeth Gersbach; Xiyu Zhang; Xiaofei Xu; Ruifen Dong; Peng Lee; Jinsong Liu; Beihua Kong; Changshun Shao; Jian-Jun Wei
Journal:  Mol Cancer Res       Date:  2013-09-17       Impact factor: 5.852

6.  Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/ JNK activation.

Authors:  Limei Xu; Xiyu Zhang; Yinuo Li; Shuhua Lu; Shan Lu; Jieyin Li; Yuqiong Wang; Xiaoxue Tian; Jian-Jun Wei; Changshun Shao; Zhaojian Liu
Journal:  Tumour Biol       Date:  2016-01-07

7.  In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.

Authors:  Yusuke Yamamoto; Gang Ning; Brooke E Howitt; Karishma Mehra; Lingyan Wu; Xia Wang; Yue Hong; Florian Kern; Tay Seok Wei; Ting Zhang; Niranjan Nagarajan; Debargha Basuli; Suzy Torti; Molly Brewer; Mahesh Choolani; Frank McKeon; Christopher P Crum; Wa Xian
Journal:  J Pathol       Date:  2016-01-09       Impact factor: 7.996

Review 8.  Mucinous borderline tumor involving fallopian tube: case report and review of the literature.

Authors:  Fangfang Liu; Junjian Wei; Danhua Shen; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

9.  KRCC1: A potential therapeutic target in ovarian cancer.

Authors:  Shailendra Kumar Dhar Dwivedi; Khader Shameer; Anindya Dey; Soumyajit Banerjee Mustafi; Xunhao Xiong; Udayan Bhattacharya; Fiifi Neizer-Ashun; Geeta Rao; Yue Wang; Cristina Ivan; Da Yang; Joel T Dudley; Chao Xu; Jonathan D Wren; Priyabrata Mukherjee; Resham Bhattacharya
Journal:  FASEB J       Date:  2019-12-23       Impact factor: 5.191

Review 10.  Coming into focus: the nonovarian origins of ovarian cancer.

Authors:  L Dubeau; R Drapkin
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.